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Theaimofthepresentstudywastoinvestigate,invivo,theeﬀectofaBrugmansiaarboreaextract(BRU),chromatographicfractions
(FA and FNA), and isolated alkaloids on the expression and the acquisition of morphine tolerance and dependence. Substances
were acutely (for expression) or repeatedly (for acquisition) administered in mice treated with morphine twice daily for 5 or 6
days, in order to make them tolerant or dependent. Morphine tolerance was assessed using the tail-ﬂick test at 1st and 5th days.
Morphine dependence was evaluated through the manifestation of withdrawal symptoms induced by naloxone injection at 6th
day. Results showed that BRU signiﬁcantly reduced the expression of morphine tolerance, while it was ineﬀective to modulate its
acquisition. Chromatographic fractions and pure alkaloids failed to reduce morphine tolerance. Conversely BRU, FA, and pure
alkaloids administrations signiﬁcantly attenuated both development and expression of morphine dependence. These data suggest
that Brugmansia arborea Lagerh might have human therapeutic potential for treatment of opioid addiction.
1.Introduction
Brugmansia arborea (L.) Lagerh. is a solanaceous shrub
n a t i v et oS o u t hA m e r i c aa n dw i d e l yc u l t i v a t e di nE u r o p ea s
an ornamental species. In Peru this plant, known with the
vernacular names of campachu or misha, is employed by the
shamans in magic and sorcery to get in touch with the gods,a s
anantinﬂammatoryandinthetreatmentofrheumaticpains.
Misha is one of the most powerful magical plants, a “hot”
species, known to act on the central nervous system [1].
Previous phytochemical studies identiﬁed some active
componentsoftheplant.Thetropanealkaloid,hyoscine,was
found in samples collected in Argentina [2]. Other tropane
alkaloids have been found in plants collected in Italy [3].
Few pharmacological studies are available in the litera-
ture about this plant. Extracts, chromatographic fractions,
and pure alkaloids showed inhibitory activity on contraction
of isolated guinea pig ileum induced both electrically and
by acetylcholine, showing a spasmolytic activity in vitro [3].
B. arborea extracts, chromatographic fractions, and pure
isolated compounds have been reported for their activity
on CNS [4]. In vitro studies demonstrated the aﬃnity of
methanol and water extracts of the plant for 5-HT1A 5-
HT2A, 5-HT2C, D1, D2, α1, and α2 receptors in binding
assays [5, 6]. These biological systems are widely involved
in the phenomenon of dependence. Particularly opioid
addiction is certainly among the most widely diﬀused with
a high rate of mortality.
Therefore, considering that B. arborea extracts and pure
alkaloids are able to reduce the morphine withdrawal in
vitro [7], the aim of the present study was to investigate the
possible activity of a methanol extract, its chromatographic
fractions, and three pure isolated compounds from B.
arborea on the expression and the acquisition of morphine
tolerance and dependence in mice.
2.MaterialsandMethods
2.1. Plant Material. Aerial parts of B. arborea were collected
in June 2008 in Conca dei Marini (Salerno, Italy). The plant
was identiﬁed by Dr. V. De Feo. A voucher specimen of the2 Evidence-Based Complementary and Alternative Medicine
plant (labeled as DF/246) was kept at the Herbarium of the
Faculty of Pharmacy, University of Salerno.
2.2. Extraction, Separation, and Identiﬁcation. One kilogram
of leaves and ﬂowers of B. arborea were oven-dried at
40◦C and powdered. The powder was extracted at room
temperature with methanol for two days. The extract was
concentrated in vacuo, giving 32g of residue. This crude
extract was called BRU. An aliquot of 3.4g of this extract
was puriﬁed on a Sephadex LH 20 column, eluting with
MeOH. One hundred ﬁfteen fractions were obtained and
combined into 15 major fractions, on the basis of their
chemical similarity as revealed by thin-layer chromatogra-
phy (TLC). Fractions 3 and 4, containing alkaloids, were
puriﬁed by RF-HPLC. Fraction 3 was puriﬁed using a
C18 μ-Bondapak column, with the following conditions:
ﬂow rate 2.0mL/min, eluent MeOH:H2O, 7:3; from this
fraction pure apoatropine (4.7mg) was obtained. From
fraction 4, puriﬁed by RF-HPL, using a C18 μ-Bondapak
column,withthefollowingconditions:ﬂowrate2.0mL/min,
eluent MeOH:H2O, 6:4, atropine (19mg) and 3α-tigloyl-
oxitropane (12.3mg) were obtained. Pure compounds were
identiﬁedbyaccurateNMRanalysesandcomparisonoftheir
spectral data with data available in literature [8, 9]. The
crude extract (BRU), the fraction containing alkaloids (FA),
the fraction not containing alkaloids (FNA), and the pure
compound (atropine, apoatropine, 3α-tigloyl-oxitropane)
were texted on mice to study the possible interaction whit
morphine.
2.3. Animals. Male CD-1 mice (Harlan SRC, Milan, Italy)
weighing 25g to 35g were used. These mice were kept in a
dedicated room, with a 12:12h light/dark cycle (lights on
at 09:00), a temperature of 20◦Ct o2 2 ◦C, and a humidity of
45%to55%.Theywereprovidedwithfreeaccesstotapwater
and food pellets (4RF18, Mucedola, Settimo Milanese, Italy).
Each mouse was used in only one experimental session.
Ethical guidelines for the investigation of experimental pain
in conscious animals were followed, and procedures were
carried out according to EEC ethical regulations for animal
research (EEC Council 86/609; D. Lgs. 27/01/1992, No. 116),
and the testing was carried out according to the European
Community Council Directive for the Care and Use of
Laboratory Animals of 24 November 1986 (86/609/EEC).
2.4. Drugs. BRU is the denomination of crude methanol
extract not puriﬁed. This extract (BRU: 7.5, 15, and
30mg/kg/5mL), its alkaloidal and nonalkaloidal fractions
(FA and FNA at 5.5 and 24,5mg/kg, resp.) and single
pure compounds (atropine, apoatropine, and 3α-tigloyl-
oxitropane,at2.2,1.8,and1.5mg/kg,resp.)weredissolvedin
water immediately before use and injected intraperitoneally
(i.p.). The same vehicle was administered to control group.
Morphine hydrochloride (Salars S.p.A, Como, Italy) was
dissolved in saline immediately before use and was admin-
istered subcutaneously (s.c.) at a dose of 10mg/kg. Naloxone
hydrochloride (Sigma, St. Louis, MO), dissolved in water
immediately before use, was administered i.p. at dose of
5mg/kg.
2.5. Induction of Morphine Tolerance. According to Abdel-
Zaher et al. [10] and Mattioli and Perfumi [11], morphine
tolerance was induced in mice treated with the adminis-
tration of morphine (10mg/kg; s.c.) twice daily at 12h
intervals for 5 days. Tolerance was evaluated by testing the
antinociceptive response to morphine on tail ﬂick test on
the 5th day, 30min after the last morphine injection, in
comparison with the 1th day. Brieﬂy, tail ﬂick test consists
of the irradiation of the lower third of the tail with an I.
R. source (Ugo Basile, Comerio, Italy). The basal predrug
latency, ranged between 2-3s, was calculated as the mean of
two trials performed at 30min interval. Then mice received
tested-compoundorrelatedvehicle,30minbeforemorphine
or saline administration. The antinociceptive activity was
evaluated, on the 5th day, 30min after the last morphine
injection. A cut-oﬀ latency of 12s was established to mini-
mize tissue damage. Antinociceptive eﬀect was expressed as a
percent of the Maximum Possible Eﬀect (MPE%) according
to the following formula:
%MPE =

Post-drug latency-baseline latency


cut-oﬀ value-baseline latency
 ×100,
(1)
where postdrug latency is tail-ﬂick latency 30min after the
last morphine dose.
2.6. Eﬀects of BRU on the Expression and the Acquisition of
Analgesic Tolerance to Morphine. In order to evaluate the
eﬀect of BRU on the acquisition (development) of morphine
tolerance, the mice (n = 8–12 for each group) were i.p.
administered with BRU (7.5, 15 and 30mg/kg), twice daily,
30min before each morphine treatment. Its eﬀects on the
expression phases of morphine tolerance were evaluated in
morphine-treated mice receiving acute administration of
BRU, 30min prior to the last morphine injection on test
day (day 5). The eﬀects of BRU on the development and
the expression of morphine tolerance were evaluated by
testing the analgesic eﬀect of morphine on tail-ﬂick test as
described in detail. In addition, the antinociceptive eﬀect of
BRU alone on antinociception was examined, by tail-ﬂick
test, in nondependent mice that received single or repeated
i.p. administration of diﬀerent doses of BRU (7.5, 15, and
30mg/kg).
2.7. Eﬀects of FA and FNA on the Expression and the Acquisi-
tion of Analgesic Tolerance to Morphine. In order to evaluate
which fraction of the total extract was responsible of the
eﬀect of BRU, the eﬀects of both FA and FNA were tested
on the expression and acquisition of analgesic tolerance to
morphine.
Therefore mice (n = 8–10 for each group) received
acute or repeated administration of FA (5.5mg/kg), FNA
(24.5mg/kg), or related vehicle following the experimental
procedure reported above. The doses of chromatographic
fractions were chosen on their percentage on 30mg/kg of
BRU.
2.8. Eﬀects of Single Alkaloids on the Expression and the
Acquisition of Analgesic Tolerance to Morphine. The threeEvidence-Based Complementary and Alternative Medicine 3
alkaloids, isolated from the alkaloid-containing fraction
(FA), were also tested on the expression and acquisition
of analgesic tolerance to morphine. For this purpose, mice
(n = 10 for each group) were administered with atropine,
apoatropine, 3α-tigloyl-oxitropane at doses of 2.2, 1.8, and
1.5mg/kg, respectively, as reported above. The dose of each
alkaloid was chosen on their percentage on 5.5mg/kg of FA.
2.9. Induction of Morphine Dependence. To develop depen-
dence, the mice were treated with morphine (10mg/kg;
s.c.) twice daily at 12h intervals for 6 days [10, 12]. Two
hours after the last dose of morphine, withdrawal syndrome
(abstinence) as an index of morphine dependence was pre-
cipitated by intraperitoneal injection of naloxone (5mg/kg)
[10, 12]. The combination of morphine with a high dose
of naloxone on day 6 has been demonstrated to induce
more severe symptoms, including autonomic signs, since
naloxone precipitates dose-dependent withdrawalsymptoms
in animals acutely or chronically dependent upon morphine
[12]. Ten minutes before naloxone treatment, the mice were
placed in a transparent acrylic cylinder (20cm diameter,
35cm high) to habituate them to the new environment.
Immediately after naloxone challenge, each mouse was
again placed gently in the cylinder and then monitored for
15min for the occurrence of withdrawal signs (jumping,
rearing, forepaw tremor, and teeth chatter). The withdrawal
symptoms are reported as a summary of all of the signs that
were seen.
2.10. Eﬀects of BRU on the Expression and the Acquisition of
MorphineDependence. Toexaminetheeﬀectsoftotalextract
on morphine dependence, BRU (7.5, 15, and 30mg/kg) was
given in mice (n = 8–12 for each group) i.p. chronically
30min prior to each morphine injection (acquisition) or
acutely before naloxone (expression) as described above.
In addition, the eﬀect of BRU alone on naloxone-induced
jumping behaviour was examined in nondependent mice.
Animals received single or repeated administration of dif-
ferent doses of BRU (7.5, 15, and 30mg/kg; i.p.) or vehicle
(5mL/kg; i.p.). The assessment of naloxone-precipitated
jumping behaviour after administration of BRU was already
described in detail.
2.11. Eﬀects of FA and FNA on the Expression and the Acqui-
sition of Morphine Dependence. To examine the eﬀects of the
two fractions of the total extract on the expression and the
acquisition of morphine dependence, FA (5.5mg/kg) and
FNA (24.5mg/kg) were tested on naloxone-precipitated
withdrawal syndrome behaviour as reported above (n = 8–
10 animals for each group).
2.12. Eﬀects of Single Alkaloids on the Expression and Acqui-
sition of Morphine Dependence. Finally single isolated alka-
loids (atropine, apoatropine, and 3α-tigloyl-oxitropane)
were administered at the dose of 2.2, 1.8, and 1.5mg/kg,
respectively, based on their percentage on the alkaloidal
fractionFA,inordertoevaluatetheireﬀectontheexpression
and development of morphine dependence (n = 10 for each
group). Experimental procedure was the same reported
above.
2.13. Statistical Analysis. The statistical analysis was per-
formed using two-way split-plot analysis of variance
(ANOVA), with treatment as the between-subject factor,
and time as the within-subject factor, to analyze morphine
tolerance. The morphine dependence data were analyzed by
one-way analysis of variance (ANOVA). When appropriate,
post hoc analysis was carried out using a Newman-Keuls
test, to determine the diﬀerences between groups. Statistical
signiﬁcance was set at P<0.05, and the data are expressed as
means ± S.E.M.
3. Results
The bioassay-oriented study of a methanol extract of Brug-
mansia arborea permitted the isolation of three tropane
alkaloids: atropine, apoatropine, and 3α-tigloil-oxitropane.
This result agrees with the available literature that reports
thatthegenusBrugmansiacontainsthisclassofalkaloids[3].
3.1. Eﬀects of BRU on the Expression and the Acquisition of
Analgesic Tolerance to Morphine. The eﬀects of BRU on the
expressionandacquisitionoftolerancetomorphine-induced
analgesia are shown in Figure 1 (Panel (a) and (b), resp.).
About expression data, overall analysis of variance revealed a
statistically signiﬁcant treatment and time eﬀect [F(4,45) =
45.091, P<0.001; F(1,4) = 204.415, P<0.001, resp.],
and interaction time × treatment eﬀects were seen on
analgesia latency in the tail-ﬂick test [F(4,45) = 19.716, P<
0.001]. The mice treated with morphine showed a maximal
antinociceptive eﬀe c t( % M P E )o nd a y1( P<0.01 between
control and morphine groups). Repeated s.c. administration
of 10mg/kg morphine twice daily to morphine-treated mice
induced a signiﬁcant decrease in the analgesia latency, on day
5i nc o m p a r i s o nt ot h a to nd a y1[ F(1,18) = 154.333; P<
0.001] (Figure 1(a)). Acute administration of BRU (7.5, 15,
and 30mg/kg) 30min before morphine injection on the test
day produced a signiﬁcant decrease in the expression of
morphinetoleranceascomparedtomorphine-vehiclegroup.
Particularly, the post hoc analysis revealed a statistically
signiﬁcant eﬀect at the highest dose of 30mg/kg (P<0.001)
(Figure 1(a)).
Acute administration of BRU to nondependent mice
(control) did not modify the analgesia latency of the treated
mice (P>0.05) (data not showed). Concerning the
eﬀect of BRU on the acquisition of analgesic tolerance to
morphine, overall analysis of variance revealed a statistically
signiﬁcant treatment and time eﬀect [F(7,74) = 22.523, P<
0.001; F(1,7) = 52.156, P<0.01, resp.], and interaction
time × treatment eﬀects were seen on analgesia latency
[F(7,74) = 10.253, P<0.001] (Figure 1(b)). The mice
treated with morphine showed a maximal antinociceptive
eﬀect (%MPE) on day 1 [F(7,74) = 17.783; P<0.001].
Post hoc analysis revealed that acute coadministration of
BRU with morphine did not modulate the analgesia at
any of the doses tested on day 1 compared to vehicle-
morphine group (P>0.05). Repeated s.c. administration of
10mg/kg morphine alone twice daily to the mice induced,
on day 5, a signiﬁcant decrease in the analgesia latency
in the tail-ﬂick test, which resulted in a 70% reduction4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Eﬀects of diﬀerent doses of Brugmansia arborea L. on the expression (a) and the acquisition (b) of tolerance to morphine-induced
analgesia. Mice were treated twice daily for 5 days with either saline or 10mg/kg morphine. BRU (0, 7.5, 15 and 30mg/kg) was administered
30min before each morphine injection (acquisition) or prior to the last morphine treatment (expression). Morphine antinociceptive eﬀect
(%MPE)wasassessedonday1andday5,asindicated.Signiﬁcantdiﬀerences: ∗∗P<0.01,comparedtocontrolgroup; ++P<0.01,compared
to related-morphine group on day 1; ◦◦P<0.01, compared to morphine group on day 5.
[F(1,18) = 41.204; P<0.001] (Figure 1(b)). Pretreatment
of the mice with 7.5, 15, and 30mg/kg BRU 30min before
each morphine injection did not inhibit the development of
tolerance to morphine analgesia at any of the doses tested
(P>0.05) (Figure 1(b)). Finally, repeated administration
of BRU to nondependent mice (control) did not modify the
analgesialatencyofthetreatedmice(P>0.05)(Figure 1(b)).
3.2. Eﬀects of FA and FNA on the Expression and the
Acquisition of Analgesic Tolerance to Morphine. As shown inEvidence-Based Complementary and Alternative Medicine 5
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Figure 2: Eﬀects of FA and FNA on the expression (a) and the acquisition (b) of tolerance to morphine-induced analgesia. Mice were treated
twice daily for 5 days with either saline or 10mg/kg morphine. FA (5.5mg/kg) and FNA (24.5mg/kg) were administered 30min before
each morphine injection (acquisition) or prior to the last morphine treatment (expression). Morphine antinociceptive eﬀect (%MPE) was
assessed on day 1 and day 5, as indicated. Signiﬁcant diﬀerences: ∗∗P<0.01, compared to control group; ++P<0.01, compared to related-
morphine group on day 1.
Figure 2, both single (Panel (a)) and repeated (Panel (b))
administration of FA (5.5mg/kg) and FNA (24.5mg/kg),
30min before morphine injection on the test day, did
not produce signiﬁcant prevention or treatment of the
morphine tolerance (P>0.05). In fact FA and FNA did not
aﬀect morphine-induced antinociception elicited by single
orrepeateddoseinjection,asconﬁrmedbystatisticalanalysis
(P>0.05).
3.3. Eﬀects of Single Alkaloids on the Expression and the
Acquisition of Analgesic Tolerance to Morphine. Figure 3
shows the eﬀects of atropine, apoatropine, and 3α-tigloyl-
oxitropane on the expression (panel (a)) and the acquisition
(Panel (b)) of analgesic tolerance to morphine. Two-way
ANOVA followed by post hoc analysis revealed that there
is no signiﬁcant diﬀerence in MPE% of morphine among
alkaloids-treated groups and vehicle-treated mice both in
the expression [F(7,64) = 45.963, P<0.001] and the
acquisition [F(7,64) = 36.520, P<0.001] test. Finally,
repeated administration of atropine, apoatropine, and 3α-
tigloyl-oxitropane to nondependent mice (control) did not
modify the analgesia latency of the treated mice (P>0.05)
(Figure 3(b)).
3.4. Eﬀects of BRU on the Expression and the Acquisition
of Morphine Dependence. Figures 4(a) and 4(b) show the6 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Eﬀects of single alkaloids on the expression (a) and the acquisition (b) of tolerance to morphine-induced analgesia. Mice were treated
twice daily for 5 days with either saline or 10mg/kg morphine. Atropine (2.2mg/kg), apoatropine (1.8mg/kg) and 3α-tigloyl-oxitropane
(1.5mg/kg) were administered 30min before each morphine injection (acquisition) or prior to the last morphine treatment (expression).
Morphine antinociceptive eﬀect (%MPE) was assessed on day 1 and day 5, as indicated. Signiﬁcant diﬀerences: ∗∗P<0.01, compared to
control group; ++P<0.01, compared to related-morphine group on day 1.Evidence-Based Complementary and Alternative Medicine 7
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Figure 4: Eﬀects of diﬀerent doses of Brugmansia arborea L. on the expression (a) and the acquisition (b) of morphine dependence. Mice were
treated twice daily for 5 days with saline or 10mg/kg morphine treatment. On the sixth day, withdrawal syndromes were precipitated by
injection of 5mg/kg naloxone, 2h after the last morphine injection. BRU (0, 7.5, 15, and 30mg/kg) was administered 30min before each
morphine injection (acquisition) or prior to naloxone injection (expression). The withdrawal symptoms are given as a summary of the
frequency of these somatic signs: jumping, rearing, forepaw tremors, and teeth chatter. Signiﬁcant diﬀerences: ∗∗P<0.01, compared to
control; +P<0.05, ++P<0.01, compared to morphine group.
eﬀects of BRU on the expression and the acquisition of
morphine dependence, respectively. Repeated administra-
tion of morphine produced physical dependence as assessed
bythesummaryofcharacteristicsetofbehaviouralresponses
including jumping, rearing, forepaw tremor, and teeth chat-
tering [F(1,18) = 29.933; P<0.001], following naloxone
challenge.
As shown in Figure 4(a), acute administration of BRU
30minpriortonaloxoneinjectionsigniﬁcantlydecreasedthe
expression of morphine dependence, as assessed by the sum-
mary of the frequencies of the signs of withdrawal syndrome
compared with frequencies of withdrawal manifestations of
morphine-dependent mice treated with vehicle [F(7.74) =
10.518;P<0.001].
Particularly, the post hoc analysis revealed a statistically
signiﬁcant and dose-dependent eﬀect at all doses tested (7.5,
15, and 30mg/kg) (P<0.001) (Figure 4(a)). No diﬀerence
was observed in control mice treated with all doses of BRU
when compared to vehicle (P>0.05).
Figure 4(b) shows the eﬀects of repeated administration
of BRU on the development of morphine dependence.
Pretreatment of the mice with BRU, 30min before each
morphine injection, attenuated the development of the
characteristic signs of withdrawal, reported as total signs
[F(7,74) = 17.774;P<0.001] (Figure 4(b)).Indeed, thepost
hoc analysis revealed a statistically signiﬁcant eﬀect both at
the highest dose of 30mg/kg (P<0.01) and at the lowest
BRU doses tested, of 7.5 and 15mg/kg (P<0.01). The mice
treated only with BRU (7.5, 15 and 30mg/kg) did not show
signiﬁcant diﬀerence in withdrawal symptoms compared to
the control group (P>0.05) (Figure 4(b)).
3.5. Eﬀects of FA and FNA on the Expression and the
Acquisition of Morphine Dependence. Overall analysis of
variance revealed a statistically signiﬁcant treatment eﬀect
[expression: F(5,54) = 12.265, P<0.001; acquisition:
F(5,54) = 11.418, P<0.001]. Posthoc analysisrevealedthat
both single-dose administration of FA (5.5mg/kg), 30min
before naloxone injection on the test day, and its repeated
injection 30min before each morphine treatment, produced
signiﬁcant decrease in the expression and the acquisition of
morphine dependence (P<0.01), respectively, as compared
to vehicle group in morphine-treated mice (Figures 5(a) and
5(b)). In fact both acutely and repeatedly FA was able to
suppress signiﬁcantly the naloxone-precipitated withdrawal
symptoms by about 50% in the morphine-dependent mice
(P<0.001). Conversely single or repeated administrations
of FNA (24.5mg/kg) were ineﬀective to prevent or treat
morphine dependence in mice (P>0.05) (Figures 5(a)
and 5(b)). On the other hand, treatment with FA or FNA
in nondependent mice did not aﬀect naloxone-precipitated
withdrawal symptoms elicited by single or repeated injection
as compared to the control group (P>0.05) (Figure 5).
3.6. Eﬀects of Single Alkaloids on the Expression and the Acqui-
sition of Morphine Dependence. As shown in Figure 6(a),
atropine, apoatropine, and 3α-tigloyl-oxitropane (2.2, 1.8,
and 1.5mg/kg resp., i.p.) administered 30min prior to8 Evidence-Based Complementary and Alternative Medicine
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Figure 5: Eﬀects of FA and FNA on the expression (a) and the acquisition (b) of morphine dependence. FA (5.5mg/kg) and FNA (24.5mg/kg)
were administered 30min before each morphineinjection twice daily for 5 days (acquisition) or prior to naloxone injection (expression). On
thesixthday,withdrawalsyndromeswereprecipitatedbyinjectionof5mg/kgnaloxone,2hafterthelastmorphineinjection.Thewithdrawal
symptoms are given as a summary of the frequency of these somatic signs: jumping, rearing, forepaw tremors, and teeth chatter. Signiﬁcant
diﬀerences: ∗∗P<0.01, compared to control; ++P<0.01, compared to morphine group.
naloxone injection inhibited about 50% naloxone-precip-
itated withdrawal symptoms compared with those of mor-
phine control group [F(7,56) = 31.552, P<0.001]. Overall
analysis of variance revealed that repeated coadministration
of atropine, apoatropine, and 3α-tigloyl-oxitropane with
morphine decreased signiﬁcantly the frequencies of the
signs of withdrawal syndrome compared with frequencies
of withdrawal manifestations of morphine-dependent mice
treated with vehicle [F(7,56) = 25.192, P<0.001]. Indeed,
the post hoc analysis revealed a statistically signiﬁcant eﬀect
for all alkaloids tested (P<0.01) (Figure 6(b)).
The mice acutely or repeatedly treated only with at-
ropine, apoatropine, and 3α-tigloyl-oxitropane did not show
signiﬁcant diﬀerence in withdrawal symptoms compared to
control animals (P>0.05) (Figures 6(a) and 6(b)).
4. Discussion
The present study has revealed the presence of three tropane
alkaloids in the methanol extract of Brugmansia arborea.
These compounds are usual in the genus [13], and no
signiﬁcant chemical diﬀerences have been found with the
same species growing in America. Moreover it valuated
the eﬀects of BRU, a methanol extract of B. arborea,i t s
alkaloidal and nonalkaloidal chromatographic fractions, or
isolated alkaloids on both the acquisition and the expression
of morphine tolerance and physical dependence in mice.
The data demonstrate that administration of BRU at high
dose attenuates the expression of morphine tolerance by
increasing the antinociceptive response, but does not atten-
uate its acquisition. On the other hand, neither alkaloidal
and nonalkaloidal fractions, nor pure alkaloids have been
proven eﬀective in preventing or countering the tolerance to
the analgesic eﬀect of morphine.
Conversely, administration of BRU attenuates both the
expression and the development of morphine dependence by
reducing the naloxone-induced behavioural and vegetative
withdrawal symptoms in a dose-dependent manner. Indeed,
BRU was eﬀective in reducing the incidence of withdrawal
symptoms in morphine-dependent mice. These data assume
greater importance when it is considered that, historically,
w i t h d r a w a ls y m p t o m sw e r eb e l i e v e dt oh a v eam a j o rr o l ei n
the relapse to drug-taking behaviour after drug abstinence
[14]. BRU eﬀects appear to be due to its alkaloidal fraction,
as demonstrated by the eﬀectiveness of single alkaloids
in preventing and countering the onset of withdrawal
symptoms induced by naloxone injection. On the other
hand, nonalkaloidal fraction was ineﬀective in reducing the
incidence of withdrawal symptoms in morphine-dependent
mice.
The results of this study support and extend previous
ﬁndings that central cholinergic receptors participate in the
expression and acquisition of opiate withdrawal symptoms
[15].
Ontheotherhand,centralcholinergicneuronshavelong
been suggested to mediate many of the signs and symptoms
of opiate withdrawal [15].
In fact pharmacological blockade of central muscarinic
receptors by antagonists, such as scopolamine, has been
widely used in treatment of drug abuse, especially in opioid
addiction [16, 17]. Moreover it was also demonstrated the
role of cholinergic system on morphine reward properties.
Indeed blockade of muscarinic receptors by diﬀerent doses
of atropine into basolateral amygdala abolished morphine-
induced place preference in rats [18].
The molecular and neurobiological mechanisms under-
lying the attenuation of morphine dependence by alkaloidsEvidence-Based Complementary and Alternative Medicine 9
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Figure 6:Eﬀectsofsinglealkaloidsontheexpression(a)andtheacquisition(b)ofmorphinedependence.Atropine,apoatropine,and3α-tigloyl-
oxitropane were administered i.p. at the dose of 2.2, 1.8, and 1.5mg/kg, respectively, 30min before each morphine injection (acquisition)
or prior to naloxone injection (expression) (n = 10 animals for each group). The withdrawal symptoms are given as a summary of the
frequency of these somatic signs: jumping, rearing, forepaw tremors, and teeth chatter. Signiﬁcant diﬀerences: ∗∗P<0.01, compared to
control; ++P<0.01, compared to morphine group.
present in B. arborea could be related to their direct blockade
of muscarinic cholinergic receptors, which have been shown
to interact with opioid receptor signalling [19].
Another possibility is that B. arborea attenuation of mor-
phine dependence is due to its indirect eﬀects on the
mesocorticolimbic dopaminergic pathway. The decreased
dopaminergic activity in the VTA induced by morphine
withdrawal increases the activity of noradrenalinergic and
cholinergic systems, which are mainly involved in morphine
withdrawal symptoms.
RecentresearchessuggestapossibleroleforM5receptors
for the treatment of opiate addiction, based on M5 AChR
brain region localization and involvement in the regulation
of striatal dopamine release and in rewarding brain stimula-
tion [20].
Moreover it was demonstrated that VTA ACh levels
played a causal role on drug seeking and reward, and
these eﬀects were strongly attenuated by local infusion of a
muscarinic antagonist, like atropine [21, 22]. Therefore B.
arborea alkaloids, based on their tropanic structure, might
prevent and counter morphine dependence by the reduction
of ACh levels on VTA brain area.
Finally, DA system plays a critical role in drug craving
and relapse, conditions that occur with dependence and
withdrawal. Administration of D1 and D2 receptors agonists
attenuated somatic withdrawal signs [23–25]. Therefore
B. arborea extract might attenuate morphine dependence
by acting directly on the mesocorticolimbic dopaminergic
pathway, since it has been demonstrated the aﬃnity of the
extract for D1 and D2 receptors [5].
In conclusion, the positive eﬀects of B. arborea extract
and its pure alkaloids in the expression and development of
morphine dependence encourage the use of the plant for the
treatment of opioid addiction.
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